Skip to main content

Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution

Journal of Neuro-Oncology volume 120, pages 597–605 (2014)Cite this article

Abstract

There are few studies reporting the incidence of leptomeningeal dissemination (LMD) in patients with glioblastoma; only small case series have been published. Consequently, there are no established standards of care for these patients. Therefore, we undertook this retrospective review to evaluate a large series of patients with glioblastoma treated at MD Anderson Cancer Center to estimate the incidence of LMD and assess the impact of a variety of treatment modalities. Analysis was performed on 595 patients with glioblastoma treated on clinical trials from 2006 to 2012. The diagnosis of LMD was made by imaging or positive cerebrospinal fluid cytology in 24 patients. An additional 12 patients with known LMD diagnosed during this same period were included to evaluate the impact of treatment on outcome for a total of 36 patients. LMD developed in 4.0 % (24/595 patients) of the clinical trial cohort. Median survival from glioblastoma diagnosis was 16.0 months. Estimated median time of glioblastoma diagnosis to LMD was 11.9 months. Median overall survival from the time of LMD diagnosis was 3.5 months. Patients treated for LMD with chemotherapy/targeted therapy and radiation had a significantly prolonged survival (7.7 months) compared to chemotherapy/targeted therapy alone, radiation alone or palliative care. LMD remains an uncommon event in patients with glioblastoma. Patients treated aggressively with chemotherapy/targeted therapy and radiation had the longest median survival following diagnosis of LMD. However, patients receiving chemotherapy/targeted therapy and radiation were younger and this may have influenced survival. Given the overall poor outcomes, improved therapeutic approaches are needed for glioblastoma patients with LMD.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1

References

  1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

    CAS  PubMed  Article  Google Scholar 

  2. Yung WA, Horten BC, Shapiro WR (1980) Meningeal gliomatosis: a review of 12 cases. Ann Neurol 8(6):605–608

    CAS  PubMed  Article  Google Scholar 

  3. Vertosick FT Jr, Selker RG (1990) Brain stem and spinal metastases of supratentorial glioblastoma multiforme: a clinical series. Neurosurgery 27(4):516–521 discussion 521–2

    PubMed  Article  Google Scholar 

  4. Arita N, Taneda M, Hayakawa T (1994) Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome. Acta Neurochir (Wien) 126(2–4):84–92

    CAS  Article  Google Scholar 

  5. Engelhard HH, Corsten LA (2005) Leptomeningeal metastasis of primary central nervous system (CNS) neoplasms. Cancer Treat Res 125:71–85

    PubMed  Article  Google Scholar 

  6. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466. doi:10.1016/S1470-2045(09)70025-7

    CAS  PubMed  Article  Google Scholar 

  7. de Groot JF, Fuller G, Kumar AJ et al (2010) Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro-Oncology. 12(3):233–242

    PubMed Central  PubMed  Article  Google Scholar 

  8. Lu KV, Chang JP, Parachoniak CA et al (2012) VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 22(1):21–35. doi:10.1016/j.ccr.2012.05.037

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  9. Clarke JL (2012) Leptomeningeal metastasis from systemic cancer. Continuum (Minneap Minn). 18(2):328–342. doi:10.1212/01

    PubMed  Google Scholar 

  10. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  11. Korshunov A, Sycheva R, Golanov A, Pronin I (2007) Gains at the 1p36 chromosomal region are associated with symptomatic leptomeningeal dissemination of supratentorial glioblastomas. Am J Clin Pathol 127(4):585–590

    CAS  PubMed  Article  Google Scholar 

  12. Kato H, Fujimura M, Kumabe T, Ishioka C, Kanamaru R, Yoshimoto T (2004) PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma. J Clin Neurosci 11(1):37–41

    CAS  PubMed  Article  Google Scholar 

  13. Herrlinger U, Wiendl H, Renninger M, Förschler H, Dichgans J, Weller M (2004) Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value. Br J Cancer 91:219–224. doi:10.1038/sj.bjc.6601953www.bjcancer.com

    CAS  PubMed Central  PubMed  Google Scholar 

  14. Chamberlain MC (2003) Combined-modality treatment of leptomeningeal gliomatosis. Neurosurgery 52(2):324–329

    PubMed  Article  Google Scholar 

  15. Le Rhun E, Taillibert S, Chamberlain MC (2013) Carcinomatous meningitis: leptomeningeal metastases in solid tumors. Surg Neurol Int 2(4(Suppl 4)):S265–S288. doi:10.4103/2152-7806.111304

    Google Scholar 

  16. Chamberlain MC (2013) Prognostic utility of neuraxis imaging in leptomeningeal metastasis: a retrospective case series. Eur Assoc Neuro Oncol 3(1):6–10

    Google Scholar 

  17. Chamberlain MC, Soffietti R, Raizer J et al (2014) Leptomeningeal metastasis: a response assessment in neuro-oncology critical review of endpoints and response criteria of published randomized clinical trials. Neuro Oncol. doi:10.1093/neuonc/nou089

    Google Scholar 

  18. Chamberlain MC (2013) Comprehensive neuraxis imaging in leptomeningeal metastasis: a retrospective case series. CNS Oncol 2(2):121–128. doi:10.2217/cns.12.45

    CAS  PubMed  Article  Google Scholar 

Download references

Conflict of interest

No conflict of interests to report.

Author information

Affiliations

  1. Department of Neurology, Baylor College of Medicine, One Baylor Plaza, MS Nb302, Houston, TX, 77030, USA

    Jacob J. Mandel

  2. Rabin Medical Center, Jabotinski Street 39, 49100, Petah-Tikva, Israel

    Shlomit Yust-Katz

  3. Quantitative Sciences - Unit 1409, The University of Texas MD Anderson Cancer Center, P. O. Box 301402, Houston, TX, 77230-1402, USA

    Jimin Wu & Diane Liu

  4. Division of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd Unit 431, Houston, TX, 77030-4009, USA

    David Cachia, John F. de Groot, Alfred W.K. Yung & Mark R. Gilbert

Authors
  1. Jacob J. Mandel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shlomit Yust-Katz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Cachia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jimin Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Diane Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John F. de Groot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alfred W.K. Yung
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mark R. Gilbert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacob J. Mandel.

Additional information

Jacob J. Mandel and Shlomit Yust-Katz have contributed equally to the manuscript.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mandel, J.J., Yust-Katz, S., Cachia, D. et al. Leptomeningeal dissemination in glioblastoma; an inspection of risk factors, treatment, and outcomes at a single institution. J Neurooncol 120, 597–605 (2014). https://doi.org/10.1007/s11060-014-1592-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-014-1592-1

Keywords

  • Glioblastoma
  • Leptomeningeal dissemination
  • Leptomeningeal gliomatosis